The persistent failure of Alzheimer's therapies targeting tau protein tangles may finally have a mechanistic explanation—and a potential workaround. While previous lithium trials in dementia patients showed disappointing results, new cellular evidence suggests the problem isn't lithium itself, but how it gets trapped by amyloid plaques before reaching its target.
Lithium chloride demonstrated robust ability to prevent tau hyperphosphorylation across multiple cellular models, including engineered human cells and inflammation-triggered mouse brain cultures. The compound specifically reduced phosphorylation at key tau sites associated with neurodegeneration, with effects varying by concentration and target location. Proteomics analysis revealed that lithium's therapeutic action extends beyond its known target GSK-3β kinase, influencing multiple phosphorylation pathways simultaneously.
This multi-target mechanism could explain why lithium shows promise in laboratory settings despite clinical setbacks. The research builds on emerging evidence that amyloid beta proteins sequester lithium salts, preventing therapeutic concentrations from reaching tau-processing machinery in patient brains. By demonstrating that lithium chloride specifically has lower affinity for amyloid aggregates compared to other lithium compounds, this work provides a roadmap for optimizing lithium-based interventions. The findings suggest that selecting lithium formulations based on their amyloid-binding properties, rather than general bioavailability, could resurrect this decades-old psychiatric medication as a neurodegeneration therapy. However, the cellular models used here cannot fully replicate the complex amyloid burden present in human Alzheimer's brains, leaving questions about real-world efficacy.